Orygen Biotecnologia SA Report issue

For profit Phase 2
Founded: Sao Paulo Brazil (2012)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2016
NCT03041766
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Orygen Biotecnologia SA

Active Ingredients

Drugs in Phase 2 Trials (2)

gla-se (2 trials)

sm14 vaccine (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Schistosomiasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2